Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lipoic acid for prevention of chemotherapy-induced peripheral neuropathy in DLBCL patients receiving R-CHOP
TCTR20261104007Phase 3Not yet recruiting
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of alpha-lipoic acid in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Faculty of Medicine, Chulalongkorn University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
alpha-lipoic acid
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on TCTR20261104007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261104007.